PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of gutGutView this articleSubmit a manuscriptReceive email alertsContact usBMJ
 
Gut. 1970 April; 11(4): 344–351.
PMCID: PMC1411413

Inhibition of peptic activity by carbenoxolone and glycyrrhetinic acid

Abstract

Carbenoxolone (Biogastrone, Berk) has been shown to reduce the peptic activity and total acidity of gastric juice obtained from anaesthetized pylorus-ligated rats without affecting significantly the volume of gastric juice secreted or the K+ concentration. Glycyrrhetinic acid was less potent in reducing peptic activity and caused no reduction in total acidity.

Antipeptic activity of carbenoxolone has also been demonstrated in vitro using the pepsin plate technique and the haemoglobin pepsin assay.

It is suggested that these actions of carbenoxolone may contribute to the increased rate of healing of peptic ulcer in patients treated with the drug.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.1M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • AITKEN MA, SPRAY GH, WALTERS G. Gastric pepsin and the excretion of uropepsinogen in anaemia. Clin Sci (Lond) 1954 Feb;13(1):119–126. [PubMed]
  • ANDERSON W. The antipeptic activity of sulphated polysaccharides. J Pharm Pharmacol. 1961 Mar;13:139–147. [PubMed]
  • ANDERSON W. The effect of a sulphated polysaccharide upon the diffusion of pepsin through mucin. J Pharm Pharmacol. 1961 Dec;13(Suppl):122–125. [PubMed]
  • Anderson W, Baillie AJ. Carrageenans and the proteolytic activity of human gastric secretion. J Pharm Pharmacol. 1967 Nov;19(11):720–728. [PubMed]
  • Anderson W, Harthill JE. Degraded and undegraded carrageenans and antipeptic activity. J Pharm Pharmacol. 1967 Jul;19(7):460–467. [PubMed]
  • Bank S, Marks IN, Palmer PE, Groll A, van Eldik E. A trial of carbenoxolone sodium in the treatment of gastric ulceration. S Afr Med J. 1967 Mar 25;41(12):297–300. [PubMed]
  • BATESON PR. A comparative in vitro evaluation of a new bismuth salt bismuth aluminate. J Pharm Pharmacol. 1958 Feb;10(2):123–131. [PubMed]
  • CARTER DV, SYKES G. The assay of enzyme activity by the plate-diffusion technique. J Pharm Pharmacol. 1961 Dec;13(Suppl):195–199. [PubMed]
  • DOLL R, HILL ID, HUTTON CF. TREATMENT OF GASTRIC ULCER WITH CARBENOXOLONE SODIUM AND OESTROGENS. Gut. 1965 Feb;6:19–24. [PMC free article] [PubMed]
  • Doll R, Langman MJ, Shawdon HH. Treatment of gastric ulcer with carbenoxolone: antagonistic effect of spironolactone. Gut. 1968 Feb;9(1):42–45. [PMC free article] [PubMed]
  • FINNEY RS, SOMERS GF. The antiinflammatory activity of glycyrrhetinic acid and derivatives. J Pharm Pharmacol. 1958 Oct;10(10):613–620. [PubMed]
  • FINNEY RS, TARNOKY AL. The pharmacological properties of glycyrrhetinic acid hydrogen succinate (disodium salt). J Pharm Pharmacol. 1960 Jan;12:49–58. [PubMed]
  • Fletcher MJ, MacKay N, Forbes CD. Assessment of possible glucocorticoid activity of carbenoxolone sodium. Br Med J. 1967 Feb 18;1(5537):412–413. [PMC free article] [PubMed]
  • Hausmann W, Tárnoky AL. Biochemical effects of short-term treatment with carbenoxolone disodium. Br J Pharmacol Chemother. 1966 Feb;26(2):412–420. [PubMed]
  • Horwich L, Galloway R. Treatment of gastric ulceration with carbenoxolone sodium: clinical and radiological evaluation. Br Med J. 1965 Nov 27;2(5473):1274–1277. [PMC free article] [PubMed]
  • LEVEY S, SHEINFELD S. The inhibition of the proteolytic action of pepsin by sulfate-containing polysaccharides. Gastroenterology. 1954 Nov;27(5):625–628. [PubMed]
  • Matts SG. Further experience with bismuth aluminate in peptic ulceration and nervous dyspepsia. Br J Clin Pract. 1965 Oct;19(10):569–571. [PubMed]
  • MIDDLETON WR, COOKE AR, STEPHEN D, SKYRING AP. BIOGASTRONE IN INPATIENT TREATMENT OF GASTRIC ULCER: A DOUBLE-BLIND STUDY. Lancet. 1965 May 15;1(7394):1030–1032. [PubMed]
  • Montgomery RD, Lawrence IH, Manton DJ, Mendl K, Rowe P. A controlled trial of carbenoxolone sodium capsules in the treatment of duodenal ulcer. Gut. 1968 Dec;9(6):704–706. [PMC free article] [PubMed]
  • PARKE DV, POLLOCK S, WILLIAMS RT. THE FATE OF TRITIUM-LABELLED BETA-GLYCYRRHETIC ACID IN THE RAT. J Pharm Pharmacol. 1963 Aug;15:500–506. [PubMed]
  • Schlamowitz M, Shaw A, Jackson WT. The nature of the binding of inhibitors to pepsin and the kinetics of inhibited peptic hydrolysis of N-acetyl-L-phenylalanyl-L-tyrosine. J Biol Chem. 1968 May 25;243(10):2821–2828. [PubMed]
  • Turpie AG, Thomson TJ. Carbenoxolone sodium in the treatment of gastric ulcer with special reference to side-effects. Gut. 1965 Dec;6(6):591–594. [PMC free article] [PubMed]
  • Whitehouse MW, Dean PD, Halsall TG. Uncoupling of oxidative phosphorylation by glycyrrhetic acid, fusidic acid and some related triterpenoid acids. J Pharm Pharmacol. 1967 Aug;19(8):533–544. [PubMed]

Articles from Gut are provided here courtesy of BMJ Group